Literature DB >> 3963555

Epidemiologic aspects of bovine anaplasmosis in semiarid range conditions of south central Idaho.

J Maas, S D Lincoln, M E Coan, K L Kuttler, J L Zaugg, D Stiller.   

Abstract

The prevalance of Anaplasma marginale-infected cows, as determined by use of the modified rapid card agglutination (MRCA) test, was measured during a 4-year period (1980-1983). The prevalence of A marginale-infected cows, defined as positive reactors on the MRCA test, remained constant (31%-37%). The apparent incidence of A marginale transmission to susceptible cows was approximately 7% from 1980 to 1981, 8% from 1981 to 1982, and no transmission from 1982 to 1983. The occasional MRCA-positive cow became negative on the MRCA test, and 1 cow was determined to be free of A marginale infection by subinoculation of 100 ml of the cow's blood into a susceptible, splenectomized calf. Dermacentor andersoni, a known vector of A marginale, was often found on the cattle and in their environment. However, A marginale was not transmitted to susceptible, splenectomized calves, using collected ticks. Of 56 calves born to MRCA-positive cows, 82% were MRCA-positive within the first 3 months of life. These calves converted to MRCA-negative status and were determined to be free of A marginale infection by subinoculation of their blood into susceptible, splenectomized calves, indicating the passive transfer of colostral antibodies.

Entities:  

Mesh:

Year:  1986        PMID: 3963555

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Evaluation of Anaplasma marginale major surface protein 3 (MSP3) as a diagnostic test antigen.

Authors:  A R Alleman; A F Barbet
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

2.  Detection of Anaplasma-marginale-infected tick vectors by using a cloned DNA probe.

Authors:  W Goff; A Barbet; D Stiller; G Palmer; D Knowles; K Kocan; J Gorham; T McGuire
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.